Latest News ROCHE ANNOUNCES FIRST RESULTS OF PROMISING NEW PROTEASE INHIBITOR AGAINST RESISTANT HIV 17-Feb-03 ROCHE UPDATES PRICING POLICY FOR PROTEASE INHIBITOR AIDS DRUGS WITHIN ACCELERATING ACCESS INITIATIVE 13-Feb-03 UPDATE ON THE MANUFACTURE OF NEW HIV DRUG FUZEON 18-Dec-02 ROCHE RECEIVES FDA CLEARANCE FOR THE COBAS AMPLISCREEN SYSTEM 05-Dec-02 ROCHE RESPONSE TO MSF LETTER 18-Nov-02 NEW DATA INDICATE TREATMENT OF HIV WITH FUZEON SHOULD BE INITIATED BEFORE ALL OTHER TREATMENT OPTIONS DEPLETED 18-Nov-02 FUZEON (ENFUVIRTIDE, T-20) DEMONSTRATES CONSISTENT BENEFIT ACROSS RANGE OF TREATMENT EXPERIENCED HIV PATIENTS 30-Sep-02 REGULATORY FILING IN EUROPEAN UNION FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20) 20-Sep-02 EUROPEAN COMMISSION APPROVES NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR TWICE DAILY) 19-Sep-02 REGULATORY FILING FOR FIRST HIV FUSION INHIBITOR FUZEON (T-20) 17-Sep-02 ROCHE AND TRIMERIS ANNOUNCE NEXT STEPS IN BRINGING FUZEON (T-20) TO HIV PATIENTS IN NEED OF NEW TREATMENT OPTIONS 02-Aug-02 U.S. FOOD AND DRUG ADMINISTRATION APPROVES NEXT GENERATION HIV-1 TEST 01-Aug-02 FIRST HEAD-TO-HEAD STUDY OF TWO BOOSTED PROTEASE INHIBITORS SHOWS SIGNIFICANT BENEFIT FOR BOOSTED SAQUINAVIR REGIMEN 10-Jul-02 NEW BOOSTED SAQUINAVIR DOSING (1000 MG SAQUINAVIR PLUS 100 MG RITONAVIR BID ) MAINTAINS HIV SUPPRESSION WHILE REDUCING TRIGLYCERIDES AND CHOLESTEROL 10-Jul-02 MAJORITY OF HIV PATIENTS FIND NEW INJECTABLE FUSION INHIBITOR T-20 (ENFUVIRTIDE) EASY TO USE 09-Jul-02 RESEARCHERS IDENTIFY PREDICTIVE AND CLINICAL VALUE OF PROVIRAL HIV-1 DNA QUANTIFICATION FOR HIV PATIENTS 09-Jul-02 NEW T-20 (ENFUVIRTIDE) RESEARCH SIGNALS NEW HOPE FOR CHILDREN AND ADOLESCENTS LIVING WITH HIV 09-Jul-02 FOUR STUDIES EXAMINE STRATEGY OF COMBINING SAQUINAVIR WITH KALETRA® IN TREATMENT-EXPERIENCED HIV PATIENTS 09-Jul-02 TREATMENT EXPERIENCED PATIENTS TWICE AS LIKELY TO ACHIEVE UNDETECTABLE HIV LEVELS WITH T-20 (ENFUVIRTIDE) THAN WITHOUT 08-Jul-02 ROCHE RENEWS ITS COMMITMENT TO THE MULTICENTER AIDS COHORT STUDY 08-Jul-02 ROCHE DIAGNOSTICS SPONSORS SURVEILLANCE PROGRAM TO HELP ENSURE FUTURE PERFORMANCE OF INDUSTRY’S HIV VIRAL LOAD ASSAYS 02-Jul-02 NEW BOOSTED SAQUINAVIR REGIMEN (1000 MG SAQUINAVIR / 100 MG RITONAVIR BID) TO TREAT HIV RECEIVES CPMP POSITIVE OPINION IN THE EU 19-Jun-02 POSITIVE RESULTS FROM SECOND PHASE III STUDY OF HIV FUSION INHIBITOR T-20 (ENFUVIRTIDE) 16-May-02 ROCHE AND TRIMERIS ANNOUNCE 24-WEEK RESULTS FROM FIRST PHASE III STUDY OF HIV FUSION INHIBITOR T-20 18-Apr-02 NEW PROMISING DRUG ADDED TO ROCHE’S STRONG HIV PORTFOLIO 15-Apr-02 STUDY PUBLISHED IN TODAY'S New England Journal of Medicine CONFIRMS ORAL VALCYTE™ TREATS AIDS-RELATED EYE DISEASE AS WELL AS IV GANCICLOVIR THERAPY 11-Apr-02 VALCYTE™ RECEIVES EU POSITIVE OPINION FOR TREATMENT OF AIDS-RELATED CMV RETINITIS 13-Mar-02 NEW EVIDENCE THAT T-20 ADDS POTENCY TO CONVENTIONAL HIV THERAPIES 19-Feb-02 START OF PILOT PROGRAMME MAY LEAD TO A NEW ERA IN HEALTHCARE DELIVERY FOR AFRICA'S DEVELOPING COUNTRIES 14-Jan-02